 |
|
Neonatal Outcomes After Prenatal Exposure to Selective Serotonin Reuptake Inhibitor Antidepressants and Maternal Depression Using Population-Based Linked Health Data
Tim F. Oberlander, MD, FRCPC;
William Warburton, PhD;
Shaila Misri, MD, FRCPC;
Jaafar Aghajanian, BSc;
Clyde Hertzman, MSc, MD, FRCPC
Arch Gen Psychiatry. 2006;63:898-906.
Context Prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants and maternal depression both alter neonatal health, and distinguishing the effects of each influence remains challenging.
Objective To determine whether exposure to SSRIs and depression differs from exposure to maternal depression alone.
Design Using population health data, records of neonatal birth outcomes were linked to records of maternal health and prenatal maternal prescriptions for SSRIs.
Setting Population of British Columbia, Canada.
Participants Mothers and their infants, representing all live births during a 39-month period (N = 119 547) (1998-2001).
Main Outcome Measures Outcomes from infants of depressed mothers treated with SSRIs (SE-D) were compared with outcomes from infants of depressed mothers not treated with medication (DE) and nonexposed controls. To control for maternal mental illness severity, propensity score matching was used to identify a comparison group of DE mothers who were similar to the SE-D mothers in characteristics in the year preceding and during pregnancy.
Results Fourteen percent of mothers were diagnosed as having depression during their pregnancy, and the incidence of prenatal SSRI exposure increased from 2.3% to 5.0% during a 39-month period. Birth weight and gestational age for SE-D infants were significantly less than for DE infants, as was the proportion of infants born at less than 37 weeks (95% confidence interval [CI], –1 to –64, –0.25 to –0.45, and –0.009 to –0.04, respectively), although differences in the incidence of birth weight less than the 10th percentile for gestational age were not significant. An increased proportion of SE-D infants had neonatal respiratory distress (13.9% vs 7.8%), jaundice (9.4% vs 7.5%), and feeding problems (3.9% vs 2.4%) compared with DE infants (95% CI of difference, 0.042-0.079, 0.003-0.334, and 0.005-0.025, respectively). When outcomes were compared between SE-D and propensity score–matched DE neonates, SE-D was associated with increased incidence of birth weight below the 10th percentile and rates of respiratory distress.
Conclusion With linked population health data and propensity score matching, prenatal SE-D exposure was associated with an increased risk of low birth weight and respiratory distress, even when maternal illness severity was accounted for.
Author Affiliations: Departments of Pediatrics (Dr Oberlander) and Psychiatry (Dr Misri) and Human Early Learning Partnership, Faculty of Graduate Studies (Drs Oberlander, Warburton, and Hertzman and Mr Aghajanian), University of British Columbia, Vancouver.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study
Oberlander et al.
Br. J. Psychiatry 2008;192:338-343.
ABSTRACT
| FULL TEXT
Bibliography for Major Depressive Disorder and Suicide
Focus 2008;6:58-62.
FULL TEXT
Prenatal Exposure to Fluoxetine Induces Fetal Pulmonary Hypertension in the Rat
Fornaro et al.
Am. J. Respir. Crit. Care Med. 2007;176:1035-1040.
ABSTRACT
| FULL TEXT
Prescribing antidepressants to pregnant women: What is a family physician to do?
Einarson and Koren
cfp 2007;53:1412-1414.
FULL TEXT
Prescrire des antidepresseurs aux femmes enceintes: Que doivent faire les medecins de famille?
Einarson and Koren
cfp 2007;53:1423-1425.
FULL TEXT
Antenatal Depression: Navigating the Treatment Dilemmas
Freeman
Am. J. Psychiatry 2007;164:1162-1165.
FULL TEXT
Effects of Antenatal Depression and Antidepressant Treatment on Gestational Age at Birth and Risk of Preterm Birth
Suri et al.
Am. J. Psychiatry 2007;164:1206-1213.
ABSTRACT
| FULL TEXT
Follow-Up on Antidepressants During Pregnancy: An Exchange of Views
JWatch Women's Health 2007;2007:6-6.
FULL TEXT
Problems With Maternal Antidepressant Treatment and Neonatal Outcomes Study
Einarson et al.
Arch Gen Psychiatry 2007;64:866-866.
FULL TEXT
Neonatal Risks of Maternal Treatment With Mood Stabilizers
Olfson and Marcus
Arch Gen Psychiatry 2007;64:866-867.
FULL TEXT
Depression during pregnancy
O'Keane and Marsh
BMJ 2007;334:1003-1005.
FULL TEXT
Externalizing and Attentional Behaviors in Children of Depressed Mothers Treated With a Selective Serotonin Reuptake Inhibitor Antidepressant During Pregnancy
Oberlander et al.
Arch Pediatr Adolesc Med 2007;161:22-29.
ABSTRACT
| FULL TEXT
How Risky Are SSRIs During Pregnancy?
JWatch Psychiatry 2006;2006:1-1.
FULL TEXT
|
